Bevacizumab with Chemotherapy for Malignant Glioma
Author Information
Author(s): Tina Mayer, Jill Lacy, Joachim Baehring
Primary Institution: Yale University School of Medicine
Hypothesis
Can bevacizumab combined with chemotherapy improve outcomes in patients with progressive malignant glioma?
Conclusion
The study confirms that bevacizumab combined with chemotherapy is effective and safe for treating progressive malignant glioma, although the treatment outcomes were lower than previously reported.
Supporting Evidence
- Median time to treatment failure was 16 weeks.
- Median overall survival was 32 weeks.
- Toxicities included arterial and venous thromboses and CNS hemorrhages.
Takeaway
Doctors gave a medicine called bevacizumab to help patients with a type of brain cancer, and it worked pretty well, but some patients had side effects.
Methodology
Retrospective review of 36 patients treated with bevacizumab after prior therapies.
Potential Biases
Patients on anticoagulation were included, which may have increased the risk of hemorrhage.
Limitations
The study involved an unselected patient population with many having received multiple prior treatments.
Participant Demographics
Median age was 50, with 22 having progressive GBM and 14 with other gliomas.
Statistical Information
Confidence Interval
[14.2–17.8, 95% C.I.] for TTF; [27.2–36.6, 95% C.I.] for OS
Want to read the original?
Access the complete publication on the publisher's website